Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Targeting CD19-negative relapsed B-acute lymphoblastic leukemia using trivalent CAR T cells.
Authors
Kristen Fousek
Baylor College of Medicine, Houston, TX
Kristen Fousek, Junji Watanabe, Ann George, Xingyue An, Heba Samir Samaha, Shoba Alaska Navai, Tiara T Byrd, Albert Jang, Hye Na Kim, Sujith Joseph, Matthew Baker, Navin Varadarajan, Meenakshi G. Hegde, Yong-Mi Kim, Nora Heisterkamp, Hisham M. Abdel-Azim, Nabil M. Ahmed
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Cell Therapies
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 121)
DOI
10.1200/JCO.2018.36.5_suppl.121
Abstract #
121
Poster Bd #
B3
Abstract Disclosures
Similar Posters
First Author: Marco L. Davila
Poster
2016 ASCO Annual Meeting
Determination of the effect of target site density on the efficacy of CD22 chimeric antigen receptor t-cell therapy to treat acute lymphoblastic leukemia.
First Author: Sang Nguyen
Poster
2022 ASCO Annual Meeting
Phase I study of donor-derived CD5 CAR T cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.
First Author: Jing Pan
Poster
2020 ASCO Virtual Scientific Program
Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity.
First Author: Rebecca Alice Gardner